Improvement of diabetes indices of care by a short pharmaceutical care program
- 296 Downloads
Objective Diabetes mellitus is a serious health problem associated with an increased mortality and morbidity. The association of improved glycemic control with sustained decrease in the rate of complications has been shown in randomized clinical trials. Pharmaceutical care is a relatively new concept in Turkey; yet, there are no recorded routine pharmaceutical care programs. Therefore, we aimed to assess the impact of a short pharmaceutical care program conducted in the community pharmacy setting, on the indices of diabetes care of type 2 diabetic patients, particularly those regarding glycemic control and high blood pressure management. Setting The study was carried out at eight community pharmacies in Pendik district of Istanbul. Method All patients who visited any of the eight pharmacies through the pre-determined 1-week period were questioned for the presence of type 2 diabetes. Patients who reported to be type 2 diabetic (n = 67) were informed about the study and invited to involve. During this prospective longitudinal study, pharmaceutical care was provided to the patients by the same clinical pharmacist. The 3 month pharmaceutical care period consisted of six pharmacy visits. Main outcome measure: The main outcome measures were the improvement in glycemic control and blood pressure control; while, weight control, self-monitoring of blood glucose, compliance and being under physician-control were also assessed. Results The study was conducted on 43 patients who accepted to involve. Fasting blood glucose was lowered by a mean of 23% over 3-months from an initial value of 167.2 mg/dl. Number of patients reaching the desired blood glucose goals increased from 16.3% to 39.5%. Systolic and diastolic blood pressures also significantly fell over 3 months (mean reductions were 10.9 mmHg for the systolic and 9.3 mmHg for the diastolic blood pressure). Number of patients reaching the desired blood pressure goal increased from 30.2% to 51.2%. Conclusion Our short-course pharmaceutical care program yielded measurable improvements in clinical indicators of diabetes and comorbidity management. The results suggest that the pharmacist is a beneficial key component of integrated care for patients with type 2 diabetes. We think that the positive results observed in this first reported pharmaceutical care program on diabetes in Turkey can be motivating and encouraging for all community pharmacists.
KeywordsDiabetes Pharmaceutical care Glycemic control Blood pressure Clinical pharmacist Turkey
This study was approved by Marmara University, Faculty of Medicine, Local Ethics Committee. Glucometer, BG electrode, glucometer-electrode calibration apparatus and control solutions were kindly provided by MediSense Optium- Abbott Pharmaceutical Inc. (Istanbul, Turkey).
The authors funded the study themselves; no external funding was applicable.
Conflict of interest
The authors have no conflicts of interest.
- 1.Matzer S, Leiter L, Daneman D, Gerstein H, Lau D, Ludwig S, et al. Clinical practice guidelines for the management of diabetes in Canada. CMAJ. 1998;159:1–29.Google Scholar
- 2.American Diabetes Association: Implications of the diabetes control and complications trial. Diabetes Care 2002; 25: 25–7.Google Scholar
- 5.The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329: 977–86.Google Scholar
- 6.The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000; 342: 381–9.Google Scholar
- 7.UK Prospective Diabetes Study (UKPDS) Group: intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352: 837–53.Google Scholar
- 8.UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854–65.Google Scholar
- 9.UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998; 317: 703–13.Google Scholar
- 10.Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. HOT Study Group: effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:1755–62.CrossRefPubMedGoogle Scholar
- 18.Berringer R, Shibley MC, Cary CC, Pugh CB, Powers PA, Rafi JA. Outcomes of a community pharmacy-based diabetes monitoring program. J Am Pharm Assoc. 1999;39:791–7.Google Scholar
- 32.Cipolle RJ, Strand LM, Morley PC. Pharmaceutical care practice: the clinician’s guide 2nd Edition The McGraw-Hill Companies, Inc. 2004 USA.Google Scholar
- 35.McLean DL, McAlister FA, Johnson JA, King KM, Makowsky MJ, Jones CA, et al. SCRIP-HTN Investigators: A randomized trial of the effect of community pharmacist and nurse care on improving blood pressure management in patients with diabetes mellitus: study of cardiovascular risk intervention by pharmacists-hypertension (SCRIP-HTN). Arch Intern Med. 2008;24(168):2355–61.CrossRefGoogle Scholar